Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Bristol-Myers, Pfizer Prepare Launch of Clot-Buster

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/24/2013 | 09:25pm CEST

--Eliquis seen generating multibillion-dollar annual sales

--Drug approved in December by FDA to reduce risk of stroke in people with irregular heartbeat

--Eliquis to enter competitive market against other new anticlotting drugs

(Adds comment from Boehringer Ingelheim spokeswoman in 13th paragraph.)

 
   By Peter Loftus 
 

Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) and Pfizer Inc. (>> Pfizer Inc.) plan to launch the anticlotting drug Eliquis in the U.S. next week, kicking off a marketing campaign that could eventually generate billions of dollars in sales.

The U.S. Food and Drug Administration approved Eliquis in late December to be used to reduce the risk of stroke and certain blood clots in people with an irregular heartbeat known as atrial fibrillation. Some analysts think the drug's annual sales could eventually top $4 billion.

Eliquis is one of a new crop of blood thinners known as anticoagulants that aim to replace--in some medical situations--an older drug, warfarin, which has been the standard of care for decades but which can be cumbersome to administer. Eliquis will compete with Xarelto, co-marketed by Johnson & Johnson (>> Johnson & Johnson) and Bayer AG (BAYN.XE, BAYRY), as well as Pradaxa from Boehringer Ingelheim GmbH, both of which are already on the market.

Bristol-Myers and Pfizer plan to launch Eliquis in the U.S. next week, and the companies are making similar plans in other countries, Bristol-Myers Chief Executive Lamberto Andreotti said on a conference call with analysts Thursday morning.

"Our teams have been working together, planning for this day, preparing for our launch," he said. The companies initially hoped to begin selling Eliquis in the U.S. last year, but the FDA extended its review after asking for more information about the drug.

Bristol-Myers spokeswoman Laura Hortas said the drug has already been shipped and is expected to be available in pharmacies soon, with full promotional activities beginning in early February. The drug has a wholesale acquisition cost of $8.35 per day.

The companies are working with health insurers and payers to secure reimbursement and patient access to the drug, said Giovanni Caforio, president of Bristol-Myers' U.S. pharmaceuticals unit. The companies also are planning a program to assist with out-of-pocket costs for the drug, he said.

Pfizer and Bristol-Myers believe Eliquis will have an edge over competing drugs because it demonstrated superiority versus warfarin in clinical trials in reducing risk of three key outcomes: stroke and systemic embolism, major bleeding and all-cause mortality.

"This unique and differentiated profile of Eliquis will resonate and will position us well against warfarin and against all other anticoagulants," Mr. Andreotti said.

Analysts have said the relatively strong clinical data for Eliquis could eventually make it the preferred choice among doctors. But a challenge for Pfizer and Bristol-Myers is to overcome "third-to-market status and general market inertia with warfarin," Leerink Swann analyst Seamus Fernandez said in a recent note. This could make for slow sales early on, picking up over time, he said.

The prescribing label for Eliquis also carries a prominent warning that discontinuing the drug could increase risk of clots and strokes, as does Xarelto's label.

William Foster, spokesman for J&J's Janssen unit, said Xarelto has the broadest profile of any of the new oral anticoagulants on the U.S. market, with six distinct uses approved by FDA. He said more than one million Xarelto prescriptions were written last year.

Boehringer Ingelheim spokeswoman Mary Lewis said Pradaxa reduced the risk of ischemic stroke and hemorrhagic stroke versus warfarin in atrial-fibrillation patients in clinical testing. "We are confident that Pradaxa will continue to be a dominant player" in the market for oral anticoagulants, she said.

Bristol-Myers discovered Eliquis and formed a partnership with Pfizer in 2007 to co-develop and co-commercialize the drug. The companies share commercialization expenses and profits equally on a global basis. The drug's U.S. patent is due to expire in 2023, according to a Bristol-Myers regulatory filing.

Write to Peter Loftus at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Bristol Myers Squibb Co., Pfizer Inc., Johnson & Johnson
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB COMPA
10/21 BRISTOL MYERS SQUIBB : Jimmy Smits Joins Stand Up to Cancer in New Public Servic..
10/20 BRISTOL MYERS SQUIBB : to Present New Data Advancing Research Across Serious Liv..
10/20 BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Accepts Bristol Myers S..
10/19 BRISTOL MYERS SQUIBB : Trevi Therapeutics Hires Dr. Helena Brett-Smith as Chief ..
10/19 BRISTOL MYERS SQUIBB : Stand Up To Cancer Awards Moffitt $2.67 Million to Study ..
10/19 BRISTOL MYERS SQUIBB : An Application for the Trademark "BEQSTIAT" Has Been File..
10/19 BRISTOL MYERS SQUIBB : BMY Extends Strategic Partnership with TARGET PharmaSolut..
10/18 JOHNSON & JOHNSON : Missouri appeals court throws out $72 million award in Johns..
10/17 BRISTOL MYERS SQUIBB : Hundreds of patients to have access to head and neck canc..
10/16 BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration (FDA) Accepts Bristol-M..
More news
News from SeekingAlpha
10/20 The Market Is Skeptical About Roche Ahead Of Major Trial Read-Outs
10/20 3 THINGS, OCTOBER 20, 2017 : Gilead's Big Day, Celgene's Bad News In Crohn's, Br..
10/19 Market Is Not Waiting For Tax Reform - Cramer's Mad Money (10/18/17)
10/18 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 18, 2017
10/18 Exploring AstraZeneca's Two-Prong Assault On Lung Cancer
Financials ($)
Sales 2017 20 540 M
EBIT 2017 5 540 M
Net income 2017 4 594 M
Debt 2017 237 M
Yield 2017 2,45%
P/E ratio 2017 23,23
P/E ratio 2018 21,47
EV / Sales 2017 5,15x
EV / Sales 2018 4,94x
Capitalization 106 B
Chart BRISTOL-MYERS SQUIBB COMPA
Duration : Period :
Bristol-Myers Squibb Compa Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 23
Average target price 60,7 $
Spread / Average Target -5,8%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY10.66%105 644
JOHNSON & JOHNSON23.29%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
MERCK AND COMPANY7.88%174 223